Cue Biopharma, Inc. (CUE)

Over the past six months, Cue Biopharma's stock price has been impacted by several events. Positive clinical data from the Phase 1b trial of CUE-101 and a strategic research collaboration with Boehringer Ingelheim for CUE-501 were reported. The company also raised approximately $20 million through a public offering and initiated an Investigator Sponsored Trial of CUE-102. Cue Biopharma and ImmunoScape entered into an exclusive in-licensing deal, and the company announced the departure of its Chief Medical Officer. Citizens reiterated a "Market Outperform" rating, and an analyst increased the price target by 25.00% to $5.10. However, the announcement and pricing of an underwritten public offering led to a significant tumble in the stock price. Overall, the stock price has decreased significantly, and the projected enterprise value and 12-month price target have been reduced.

As a clinical-stage biopharmaceutical company, Cue Biopharma does not have direct demand seasonality for its products. However, there is an observed seasonality in investor interest or stock performance, with historical data suggesting a potential seasonal pattern in how investors approach the stock.

Cue Biopharma, Inc., founded in 2015 and based in Cambridge, United States, is a clinical-stage biotechnology company focused on developing precision immunotherapies. The company's Immuno-STAT™ platform delivers cytokine payloads directly to antigen-specific T cells. The CUE-100 series (Oncology) includes CUE-101, in Phase 1b clinical trials for HPV+ recurrent metastatic head and neck squamous cell carcinoma, and CUE-102, also in Phase 1b clinical trials for late-line recurrent metastatic WT1+ cancers. The CUE-400 series (Autoimmune Diseases) features CUE-401, a preclinical candidate designed to induce antigen-specific Tregs. The CUE-500 series (Targeted Cell Depletion) includes CUE-501, a preclinical treatment for autoimmune disease via anti-viral T cell-mediated depletion of B cells.

Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts, United States, with primary operations and clinical development activities focused within the United States.

Cue Biopharma's brand reputation has been impacted by its stock performance and analyst ratings. The stock has significantly underperformed both the US Biotechs industry and the broader US Market. While some analysts have given a "Buy" or "Strong Buy" consensus rating, there is also a "Sell" consensus rating. The decrease in projected enterprise value and the reduction in the 12-month price target suggest diminished market confidence. Events such as the public offering and the departure of the Chief Medical Officer likely contributed to a negative perception.

Cue Biopharma, Inc. has 61 institutional owners and shareholders holding a total of 18,632,698 shares. Major institutional owners include Bleichroeder LP, Catalytic Wealth RIA, LLC, Vanguard Group Inc., and BlackRock, Inc. Individual insiders who own company stock include Daniel R Passeri, Anish Suri, Peter A Kiener, and Pasha Sarraf.